Kythera Biopharmaceuticals Inc (KYTH) financial statements (2020 and earlier)

Company profile

Business Address 27200 WEST AGOURA ROAD
CALABASAS, CA 91301
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10016779
Cash and cash equivalents2911279
Short-term investments7056 
Restricted cash and investments 58
Prepaid expense and other current assets11
Other undisclosed current assets1  
Total current assets:10117388
Noncurrent Assets
Property, plant and equipment200
Regulated entity, other noncurrent assets2911
Restricted cash and investments  8
Other noncurrent assets0 
Prepaid expense and other noncurrent assets00
Other undisclosed noncurrent assets(29)(1)(1)
Total noncurrent assets:209
TOTAL ASSETS:10317396
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12109
Accounts payable532
Accrued liabilities235
Employee-related liabilities532
Debt561
Other liabilities1  
Other undisclosed current liabilities336
Total current liabilities:211816
Noncurrent Liabilities
Long-term debt and lease obligation2363
Long-term debt, excluding current maturities2363
Liabilities, other than long-term debt100
Deferred revenue and credits 00
Other liabilities1  
Other undisclosed noncurrent liabilities  8
Total noncurrent liabilities:23611
Total liabilities:442427
Stockholders' equity
Stockholders' equity attributable to parent5915069
Additional paid in capital367322189
Accumulated other comprehensive income (loss)(0)0 
Accumulated deficit(308)(172)(120)
Total stockholders' equity:5915069
TOTAL LIABILITIES AND EQUITY:10317396

Income statement (P&L) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
  20
Cost of revenue
(Cost of Goods and Services Sold)
  (2)
Gross profit:  18
Operating expenses(132)(50)(54)
Operating loss:(132)(50)(36)
Nonoperating income
(Investment Income, Nonoperating)
00 
Interest and debt expense(4)(2)(0)
Loss from continuing operations before income taxes:(136)(52)(36)
Income tax benefit 2415
Net loss:(136)(28)(21)
Other undisclosed net loss attributable to parent(0)(24)(16)
Net loss available to common stockholders, diluted:(136)(52)(37)

Comprehensive Income ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Net loss:(136)(28)(21)
Other comprehensive income (loss)(0)0 
Comprehensive loss:(136)(28)(21)
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)(24)(16)
Comprehensive loss, net of tax, attributable to parent:(136)(52)(37)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: